Opioid Addiction Opportunity Assessment 2024 and Forecasts to 2033
November 25, 2024 07:07 ET
|
Research and Markets
Dublin, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The "Opioid Addiction: Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering.There will be an overall increase in...
X Waiver Mini-Course Expands Emergency Clinician Recognition and Treatment of Opioid Withdrawal, Study Finds
April 13, 2022 08:00 ET
|
American College of Medical Toxicology
Phoenix, AZ, April 13, 2022 (GLOBE NEWSWIRE) -- “A Brief Educational Intervention to Increase ED Initiation of Buprenorphine for Opioid Use Disorder (OUD)” was a study funded by a grant to the...
Spark Biomedical, Inc., granted $2.49M by the National Institute of Health HEAL Initiative to use neuromodulation as adjunctive therapy for neonatal opioid withdrawal syndrome
March 03, 2022 11:22 ET
|
Spark Biomedical
Dallas, Texas, March 03, 2022 (GLOBE NEWSWIRE) -- Building on Phase I clinical trial success (Jenkins, Khodaparast, et al., 2021), Spark Biomedical, Inc., and The Medical University of South...
Spark Biomedical, Inc enlists the expertise of former Deputy Secretary of the U.S. Department of Health and Human Services, Eric D. Hargan, to help make novel opioid withdrawal treatment more accessible and affordable for patients
November 04, 2021 10:25 ET
|
Spark Biomedical
Dallas, TX, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc, a leader in wearable neurostimulation for opioid withdrawal relief, today announced the Company will join forces with Eric D....
Spark Biomedical’s Sparrow Therapy System™ receives FDA Clearance for Opioid Withdrawal Relief in Adults
January 04, 2021 16:38 ET
|
Spark Biomedical
Dallas, TX, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc. announced today that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to The Sparrow Therapy System, a...
Spark Biomedical Receives FDA Breakthrough Device Designation for Infant Transcutaneous Auricular Neurostimulation (tAN™) Device, The Roo™ System
December 15, 2020 14:14 ET
|
Spark Biomedical
Dallas, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc. announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Roo System: a...
Nine Foremost Pain Management Physicians Join the Spark Biomedical, Inc. Medical Advisory Board
August 28, 2020 09:30 ET
|
Spark Biomedical
Dallas, Texas, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Spark Biomedical, developer of the Sparrow ™ Therapy System — a discrete, wearable, over-the-ear, medical device designed for opioid withdrawal...
DEA States The natural herb Kratom An Imminent Hazard to Public Safety
February 09, 2018 20:10 ET
|
TheRecover.com
SAN DIEGO, Feb. 09, 2018 (GLOBE NEWSWIRE) -- A new story published by The Recover talks controversy regarding the FDA’s decision to classify the herbal supplement Kratom as an opioid. After months...